Top Page
Daré Bioscience
(NASDAQ:DARE)
Daré Bioscience (DARE) vs. SPDR S&P 500 ETF (SPY)
Daré Bioscience Business Overview & Revenue Model
Daré Bioscience Earnings Call Summary
Daré Bioscience Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.91K | 9.78K | 2.81M | 10.00M | 0.00 | 0.00 |
| Gross Profit | -14.22M | -14.29M | 2.77M | 9.95M | -26.41K | -43.23K |
| EBITDA | -21.82M | -23.41M | -30.90M | -31.36M | -39.04M | -27.36M |
| Net Income | -1.68M | -4.05M | -30.16M | -30.95M | -38.33M | -27.40M |
Balance Sheet | ||||||
| Total Assets | 18.62M | 22.10M | 21.28M | 43.83M | 55.81M | 7.55M |
| Cash, Cash Equivalents and Short-Term Investments | 10.33M | 15.70M | 10.48M | 34.67M | 51.67M | 4.67M |
| Total Debt | 3.57M | 1.30M | 1.40M | 488.74K | 270.55K | 756.84K |
| Total Liabilities | 28.18M | 28.11M | 26.33M | 32.71M | 17.05M | 8.70M |
| Stockholders Equity | -9.56M | -6.01B | -5.05M | 11.11M | 38.75M | -1.15M |
Cash Flow | ||||||
| Free Cash Flow | -13.43M | 4.82M | -39.49M | -18.15M | -28.78M | -25.25M |
| Operating Cash Flow | -12.99M | 5.39M | -38.86M | -18.09M | -28.76M | -25.23M |
| Investing Cash Flow | -445.15K | -573.05K | -629.43K | -63.07K | -14.52K | -17.63K |
| Financing Cash Flow | 572.72K | 433.83K | 15.64M | 1.34M | 75.85M | 25.13M |
Daré Bioscience Technical Analysis
Daré Bioscience Risk Analysis
Daré Bioscience Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.44B | -0.20 | -46.00% | 2.27% | 22.80% | -2.27% | |
50 Neutral | $27.15M | ― | -85.45% | ― | 61.15% | 54.71% | |
50 Neutral | $17.97M | ― | 597.53% | ― | 88.13% | 92.45% | |
48 Neutral | $33.24M | ― | -1738.36% | ― | -43.55% | 69.81% | |
41 Neutral | $34.95M | ― | -312.77% | ― | ― | 61.18% | |
40 Underperform | $5.79M | ― | -67.73% | ― | 43.03% | 81.75% | |
30 Underperform | $27.55M | ― | -2880.11% | ― | ― | 31.09% |
Daré Bioscience Corporate Events
On July 24, 2025, Daré Bioscience received confirmation from Nasdaq that it met the stockholders’ equity requirement, ensuring compliance with the Nasdaq Capital Market’s listing rules. However, the company will be under a Mandatory Panel Monitor for one year, and any non-compliance within this period could lead to a delist determination without the opportunity for a compliance plan or additional time to regain compliance.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
On July 14, 2025, Daré Bioscience announced positive interim results from its Phase 3 clinical trial of Ovaprene®, a hormone-free monthly intravaginal contraceptive. The trial’s data safety monitoring board recommended continuing the study without modification, as no new safety concerns were identified. Approximately 9% of participants experienced pregnancy, aligning with expectations, while 17% discontinued due to vaginal odor. Participants expressed a high likelihood of using Ovaprene if available, highlighting its potential to meet the demand for hormone-free contraceptive options. Bayer has the option to commercialize Ovaprene in the U.S., potentially providing significant financial benefits to Daré.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
On July 9, 2025, Daré Bioscience reconvened its stockholder meeting initially held on June 12, 2025, which was adjourned due to a lack of quorum. During the meeting, four proposals were voted on, including the election of Class II directors, the ratification of Haskell & White LLP as the independent accounting firm for 2025, approval of executive compensation, and the 2022 Plan Amendment, all of which were passed by the stockholders.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
On June 24, 2025, Daré Bioscience received approval from the Nasdaq Hearings Panel for its modified plan to regain compliance with Nasdaq Listing Rules, with a conditional continued listing period until August 12, 2025. The company must demonstrate compliance with either the Stockholders’ Equity Rule or the Minimum MVLS Rule by July 31, 2025, or face potential delisting, which could impact its stock market presence and capital-raising capabilities.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.